TUKYSA
Drug
Seagen Inc.
Total Payments
$257.3M
Transactions
47,212
Doctors
7,909
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $60.6M | 4,358 | 1,037 |
| 2023 | $84.1M | 14,118 | 4,696 |
| 2022 | $62.7M | 13,415 | 3,802 |
| 2021 | $32.7M | 11,550 | 3,116 |
| 2020 | $17.2M | 3,771 | 1,224 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $251.5M | 18,892 | 97.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.3M | 1,213 | 1.3% |
| Consulting Fee | $1.0M | 448 | 0.4% |
| Food and Beverage | $648,160 | 25,010 | 0.3% |
| Travel and Lodging | $514,282 | 1,363 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $198,500 | 69 | 0.1% |
| Education | $67,726 | 181 | 0.0% |
| Grant | $57,500 | 7 | 0.0% |
| Honoraria | $42,252 | 29 | 0.0% |
Payments by Type
Research
$251.5M
18,892 transactions
General
$5.8M
28,320 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| The CompassHER2 Trials (COMprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib | Seagen Inc. | $74.7M | 0 |
| Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | Seagen Inc. | $42.5M | 0 |
| Targeted Agent and Profiling Utilization Registry | Seagen Inc. | $12.1M | 0 |
| A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | PFIZER INC. | $10.7M | 0 |
| A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) | Seagen Inc. | $9.0M | 0 |
| BRIDGET SECONDARY BRAIN METASTASES PREVENTION AFTER ISOLATED INTRACRANIAL PROGRESSION ON MAINTENANCE HERCEPTINPERJETA OR TDM1 IN PATIENTS WITH ADVANCED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 BREAST CANCER WITH THE ADDITION OF TUCATINIB | PFIZER INC. | $8.9M | 0 |
| Phase 1b/2 Open-label single arm study to evaluate safety and efficacy of tucatinib in combination with palbociclimb and letrozole in subjects with hormone receptor positive and HER2-positive metastatic breast cancer | Seagen Inc. | $6.1M | 0 |
| A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC) | Seagen Inc. | $5.8M | 0 |
| TARGETED AGENT AND PROFILING UTILIZATION REGISTRY | PFIZER INC. | $5.7M | 0 |
| A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | Seagen Inc. | $5.1M | 0 |
| A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer | Seagen Inc. | $5.1M | 0 |
| AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZAMAB AND MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | PFIZER INC. | $5.1M | 0 |
| A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) | Seagen Inc. | $4.9M | 0 |
| An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzamab and mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer. | Seagen Inc. | $4.1M | 0 |
| A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | PFIZER INC. | $4.0M | 0 |
| THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB | PFIZER INC. | $4.0M | 0 |
| STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER | PFIZER INC. | $3.8M | 0 |
| Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | Seagen Inc. | $3.1M | 0 |
| BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on maintenance Herceptin/Perjeta or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib | Seagen Inc. | $3.0M | 0 |
| A Phase 1b Dose Escalation Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers | Seagen Inc. | $2.8M | 0 |
Top Doctors Receiving Payments for TUKYSA — Page 317
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Kathleen Burns | Nurse Practitioner | Duarte, CA | $3.98 | 1 |
| , NP | Family | Johnson City, NY | $3.67 | 1 |
| , MD | Gynecologic Oncology | Philadelphia, PA | $3.25 | 1 |
| , D.O | Medical Oncology | West Reading, PA | $3.14 | 1 |
| , ARNP, MSN, AGPCNP-BC | Adult Health | Seattle, WA | $3.12 | 1 |
| Breanna Byrd | Registered Nurse | Baton Rouge, LA | $2.48 | 1 |
| , NP | Family Health | Bridgeton, MO | $2.11 | 1 |
| Roxy Gazaway | Family | Chattanooga, TN | $2.11 | 1 |
| , NP | Nurse Practitioner | Chattanooga, TN | $2.11 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Ashland, KY | $1.01 | 1 |
Ad
Manufacturing Companies
- Seagen Inc. $196.7M
- PFIZER INC. $60.6M
- PBG PUERTO RICO LLC $2,275
- ARRAY BIOPHARMA INC $1.01
Product Information
- Type Drug
- Total Payments $257.3M
- Total Doctors 7,909
- Transactions 47,212
About TUKYSA
TUKYSA is a drug associated with $257.3M in payments to 7,909 healthcare providers, recorded across 47,212 transactions in the CMS Open Payments database. The primary manufacturer is Seagen Inc..
Payment data is available from 2020 to 2024. In 2024, $60.6M was paid across 4,358 transactions to 1,037 doctors.
The most common payment nature for TUKYSA is "Unspecified" ($251.5M, 97.7% of total).
TUKYSA is associated with 20 research studies, including "The CompassHER2 Trials (COMprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib" ($74.7M).